Skip to main content
. Author manuscript; available in PMC: 2016 Nov 4.
Published in final edited form as: Small. 2015 Sep 2;11(41):5483–5496. doi: 10.1002/smll.201501284

Figure 4.

Figure 4

Antigen and adjuvant loaded into separate nanoparticles for programmed immune responses. (A) Schematic illustrating ex vivo DC pulsing with an antigen carrying programmed nanoparticles (pNP) (PLGA OVA/ICG) and adjuvant encapsulating pNP (PLGA R837/STAT3 siRNA), and the antitumor immunity effects once pulsed DCs are administered. (B) Antitumor activity of DCs pulsed with pNPs. One week after immunization with pulsed DCs, mice were challenged with E.G7-OVA tumor cells, and tumor volume was measured every 3 days. Representative photographs are shown for each group. Reproduced with permission.[146] Copyright 2013, Elsevier.